Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MIRM NASDAQ:SRRK NASDAQ:VERV NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMIRMMirum Pharmaceuticals$76.19+4.0%$72.02$36.88▼$78.54$3.68B0.81853,434 shs517,224 shsSRRKScholar Rock$32.40+1.6%$33.86$22.71▼$46.98$3.07B0.423.54 million shs3.83 million shsVERVVerve Therapeutics$11.13$11.13$2.86▼$11.40$992.13M2.233.94 million shsN/AVKTXViking Therapeutics$35.12+6.3%$29.33$18.92▼$81.73$3.72B0.645.40 million shs5.32 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMIRMMirum Pharmaceuticals+1.54%-0.62%-1.39%+38.79%+84.26%SRRKScholar Rock-6.94%-19.24%+0.73%-22.48%+11.85%VERVVerve Therapeutics0.00%0.00%0.00%+1.00%+121.27%VKTXViking Therapeutics-2.54%+4.82%+33.21%+4.49%-49.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMIRMMirum Pharmaceuticals$76.19+4.0%$72.02$36.88▼$78.54$3.68B0.81853,434 shs517,224 shsSRRKScholar Rock$32.40+1.6%$33.86$22.71▼$46.98$3.07B0.423.54 million shs3.83 million shsVERVVerve Therapeutics$11.13$11.13$2.86▼$11.40$992.13M2.233.94 million shsN/AVKTXViking Therapeutics$35.12+6.3%$29.33$18.92▼$81.73$3.72B0.645.40 million shs5.32 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMIRMMirum Pharmaceuticals+1.54%-0.62%-1.39%+38.79%+84.26%SRRKScholar Rock-6.94%-19.24%+0.73%-22.48%+11.85%VERVVerve Therapeutics0.00%0.00%0.00%+1.00%+121.27%VKTXViking Therapeutics-2.54%+4.82%+33.21%+4.49%-49.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMIRMMirum Pharmaceuticals 3.00Buy$76.500.41% UpsideSRRKScholar Rock 3.07Buy$48.6050.00% UpsideVERVVerve Therapeutics 2.33Hold$14.5730.92% UpsideVKTXViking Therapeutics 2.86Moderate Buy$86.42146.06% UpsideCurrent Analyst Ratings BreakdownLatest VERV, SRRK, VKTX, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/9/2025SRRKScholar RockBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$53.0010/8/2025MIRMMirum PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SRRKScholar RockWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VKTXViking TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/29/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.009/27/2025MIRMMirum PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SRRKScholar RockWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025VKTXViking TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/25/2025MIRMMirum PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/24/2025SRRKScholar RockPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$52.00 ➝ $51.009/24/2025MIRMMirum PharmaceuticalsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMIRMMirum Pharmaceuticals$336.89M11.36N/AN/A$4.70 per share16.21SRRKScholar Rock$33.19M93.84N/AN/A$3.94 per share8.22VERVVerve Therapeutics$32.33M30.69N/AN/A$5.83 per share1.91VKTXViking TherapeuticsN/AN/AN/AN/A$7.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMIRMMirum Pharmaceuticals-$87.94M-$1.21N/AN/AN/A-13.65%-24.76%-8.50%11/11/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)VERVVerve Therapeutics-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%N/AVKTXViking Therapeutics-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)Latest VERV, SRRK, VKTX, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025MIRMMirum Pharmaceuticals-$0.11N/AN/AN/A$130.11 millionN/A11/11/2025Q3 2025SRRKScholar Rock-$0.88N/AN/AN/AN/AN/A10/22/2025Q3 2025VKTXViking Therapeutics-$0.71N/AN/AN/AN/AN/A8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31-$0.12+$0.19-$0.12$107.91 million$127.79 million8/6/2025Q2 2025SRRKScholar Rock-$0.66-$0.98-$0.32-$0.98$0.11 millionN/A7/23/2025Q2 2025VKTXViking Therapeutics-$0.44-$0.58-$0.14-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMIRMMirum Pharmaceuticals1.213.132.97SRRKScholar Rock0.216.336.33VERVVerve TherapeuticsN/A9.849.84VKTXViking TherapeuticsN/A25.8625.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMIRMMirum PharmaceuticalsN/ASRRKScholar Rock91.08%VERVVerve Therapeutics97.11%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipMIRMMirum Pharmaceuticals14.36%SRRKScholar Rock13.30%VERVVerve Therapeutics19.30%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMIRMMirum Pharmaceuticals14050.24 million43.02 millionOptionableSRRKScholar Rock14096.13 million83.34 millionOptionableVERVVerve Therapeutics11089.14 million71.94 millionOptionableVKTXViking Therapeutics20112.44 million107.84 millionOptionableVERV, SRRK, VKTX, and MIRM HeadlinesRecent News About These CompaniesViking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025October 15 at 4:05 PM | prnewswire.comViking Therapeutics (VKTX) Projected to Post Earnings on WednesdayOctober 15 at 2:35 AM | marketbeat.comViking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to NoteOctober 14 at 6:51 PM | zacks.comViking Therapeutics (NASDAQ:VKTX) Shares Down 2.5% - Should You Sell?October 14 at 5:40 PM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 1% - What's Next?October 13 at 5:57 PM | marketbeat.comIFP Advisors Inc Acquires 10,048 Shares of Viking Therapeutics, Inc. $VKTXOctober 13 at 6:08 AM | marketbeat.comM&A Speculation Fuels Volatility in Viking Therapeutics SharesOctober 12 at 4:07 AM | aktiencheck.deAViking Therapeutics, Inc. $VKTX Shares Acquired by Blair William & Co. ILOctober 12 at 4:00 AM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Down 4.1% - What's Next?October 10, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Purchases New Stake in Viking Therapeutics, Inc. $VKTXOctober 10, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 8.1% - Should You Buy?October 10, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by BrokeragesOctober 9, 2025 | americanbankingnews.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Rating of "Moderate Buy" by BrokeragesOctober 9, 2025 | marketbeat.comViking Therapeutics' (VKTX) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 8, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 2.6% - Here's WhyOctober 8, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Down 2.3% - Here's WhyOctober 7, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 8.6% - Here's What HappenedOctober 6, 2025 | marketbeat.comWhy Viking Therapeutics (VKTX) Is Up 15.1% After Acquisition Buzz and Analyst Focus on Its PipelineOctober 6, 2025 | finance.yahoo.comViking Therapeutics:Â A Speculative BuyOctober 4, 2025 | seekingalpha.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 6.6% - What's Next?October 3, 2025 | marketbeat.comViking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to KnowOctober 2, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Biotech Breakouts: 3 Stocks With Massive Upside PotentialBy Chris Markoch | September 17, 2025VERV, SRRK, VKTX, and MIRM Company DescriptionsMirum Pharmaceuticals NASDAQ:MIRM$76.19 +2.91 (+3.97%) Closing price 04:00 PM EasternExtended Trading$76.18 -0.02 (-0.02%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Scholar Rock NASDAQ:SRRK$32.40 +0.50 (+1.57%) Closing price 04:00 PM EasternExtended Trading$32.62 +0.23 (+0.69%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Verve Therapeutics NASDAQ:VERVVerve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Viking Therapeutics NASDAQ:VKTX$35.12 +2.07 (+6.26%) Closing price 04:00 PM EasternExtended Trading$35.15 +0.03 (+0.09%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
